A New Player in the Amarin Buyout Saga?

Ever since Amarin's (Nasdaq: AMRN  ) new drug Vascepa, which lowers triglyceride levels, was approved in July, the biotech space has been rife with talk of a buyout. It has been previously reported that AstraZeneca  (NYSE: AZN  ) might be considering this purchase, but now an unexpected new company has stepped into the story.

In this video, Motley Fool health care analyst Max Macaluso discusses Teva Pharmaceutical's  (NYSE: TEVA  ) possible interest in Amarin and whether this drugmaker would actually be a better match than AstraZeneca.

The biotech space can make or break investors over-night, so the success of Amarin's new triglyceride lowering drug is key to the company's future success or failure. Many are optimistic about the drug's success, but the drama surrounding a potential buyout could mean everything for this stock's story. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2115652, ~/Articles/ArticleHandler.aspx, 8/23/2014 3:54:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement